Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vernalis cures its Frova migraine

Vernalis plc was cash strapped after buying back North American marketing rights for its Frova frovatriptan migraine drug from Elan Corp. plc in May. But a new deal selling those rights to Endo Pharmaceutical Holdings Inc. spares Vernalis the need to return to the market to pay off its debt to ELN. In addition, the new terms look more advantageous to Vernalis.

The original deal was unwound so ELN

Read the full 692 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers